Critical Survey: Interpace Diagnostics Group (NASDAQ:IDXG) vs. Pulse Biosciences (NASDAQ:PLSE)

Interpace Diagnostics Group (NASDAQ:IDXG) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Earnings and Valuation

This table compares Interpace Diagnostics Group and Pulse Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $21.90 million 0.75 -$12.19 million ($0.43) -1.00
Pulse Biosciences N/A N/A -$37.54 million ($2.20) -6.66

Interpace Diagnostics Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Interpace Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Diagnostics Group and Pulse Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -77.55% -58.48% -31.60%
Pulse Biosciences N/A -77.93% -70.28%

Analyst Recommendations

This is a summary of current recommendations for Interpace Diagnostics Group and Pulse Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 3 0 3.00
Pulse Biosciences 0 0 1 0 3.00

Interpace Diagnostics Group currently has a consensus price target of $2.33, indicating a potential upside of 443.39%. Pulse Biosciences has a consensus price target of $27.00, indicating a potential upside of 84.30%. Given Interpace Diagnostics Group’s higher possible upside, equities analysts plainly believe Interpace Diagnostics Group is more favorable than Pulse Biosciences.

Insider and Institutional Ownership

18.7% of Interpace Diagnostics Group shares are held by institutional investors. Comparatively, 10.2% of Pulse Biosciences shares are held by institutional investors. 48.0% of Interpace Diagnostics Group shares are held by company insiders. Comparatively, 48.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Interpace Diagnostics Group has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Summary

Interpace Diagnostics Group beats Pulse Biosciences on 10 of the 12 factors compared between the two stocks.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.